Literature DB >> 12735568

Intra-atrial temperatures in radiofrequency endocardial ablation: histologic evaluation of lesions.

Teresa Santiago1, João Q Melo, Rosa H Gouveia, Ana P Martins.   

Abstract

BACKGROUND: Because of the limited information on the effects of ablation in human tissues, we studied intra-atrial temperatures during endocardial radiofrequency applications. We correlated the intra-tissue temperatures with the tissue thickness and with the histologic appearance of the lesions.
METHODS: Radiofrequency currents were delivered to human atrial tissue, simulating conditions in endocardial ablation during surgery at set temperature of 70 degrees and 80 degrees C, and intra-tissue temperatures were measured with thermocouples. Radiofrequency applications at 70 degrees C were performed in patients undergoing mitral valve surgery and biopsy specimens were obtained. Samples from in vitro studies and from patients were assessed histologically.
RESULTS: The subepicardial temperatures were usually over 60 degrees C in applications in vitro at 70 degrees C and over 70 degrees C in applications at 80 degrees C. Values were higher when the interior of the tissue was warmer than its surface as a result of consecutive radiofrequency applications over the same area. Histologic examination of 12 in vitro samples showed that 10 had transmural lesions. Five of 10 samples from patients with mitral valve surgery had lesions confined to the endocardium, 3 had damaged variable portions of the myocardium, and 2 had transmural lesions.
CONCLUSIONS: Although it is possible to obtain transmural lesions in vitro and in vivo with endocardial applications at 70 degrees C, it is significantly more difficult to achieve transmural lesions in patients with mitral valve disease than in normal atrial tissue in vitro. Consecutive applications can raise the intra-tissue temperatures to values significantly higher than those used for application. Our findings suggest that the composition of the endocardium and of the myocardium is a major determinant in lesion formation.

Entities:  

Mesh:

Year:  2003        PMID: 12735568     DOI: 10.1016/s0003-4975(02)04990-1

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

Review 1.  Ablation technology for the surgical treatment of atrial fibrillation.

Authors:  Spencer J Melby; Richard B Schuessler; Ralph J Damiano
Journal:  ASAIO J       Date:  2013 Sep-Oct       Impact factor: 2.872

2.  A new era in the surgical treatment of atrial fibrillation: the impact of ablation technology and lesion set on procedural efficacy.

Authors:  Spencer J Melby; Andreas Zierer; Marci S Bailey; James L Cox; Jennifer S Lawton; Nabil Munfakh; Traves D Crabtree; Nader Moazami; Charles B Huddleston; Marc R Moon; Ralph J Damiano
Journal:  Ann Surg       Date:  2006-10       Impact factor: 12.969

3.  Mathematical modeling of epicardial RF ablation of atrial tissue with overlying epicardial fat.

Authors:  Ana González Suárez; Fernando Hornero; Enrique J Berjano
Journal:  Open Biomed Eng J       Date:  2010-02-04

Review 4.  The surgical treatment of atrial fibrillation.

Authors:  Anson M Lee; Spencer J Melby; Ralph J Damiano
Journal:  Surg Clin North Am       Date:  2009-08       Impact factor: 2.741

Review 5.  Surgical ablation devices for atrial fibrillation.

Authors:  Shelly C Lall; Ralph J Damiano
Journal:  J Interv Card Electrophysiol       Date:  2007-12       Impact factor: 1.900

Review 6.  Surgical treatment of atrial fibrillation : a systematic review.

Authors:  K Khargi; A Keyhan-Falsafi; B A Hutten; H Ramanna; B Lemke; T Deneke
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2007-06

7.  Human comparative experimental study of surgical treatment of atrial fibrillation by epicardial techniques.

Authors:  Jean-Marc El Arid; Thomas Sénage; Claire Toquet; Ousama Al Habash; Antoine Mugniot; Olivier Baron; Jean-Christian Roussel
Journal:  J Cardiothorac Surg       Date:  2013-05-31       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.